Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
| Price | $1.10 |
|---|---|
| Market cap | $102.28M |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| Exchange | NASDAQ |
| 52-week range | 0.491-2.25 |
| Beta | 3.53 |
Explore CTOR's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.